Also trades as: OABI (NASDAQ) · $vol 7M
OABIW NASDAQ
OmniAb, Inc.
1W: +79.9%
1M: +10.4%
3M: +330.6%
YTD: +291.4%
1Y: -17.6%
3Y: -3.1%
$0.39
+0.15 (+61.46%)
Credit Risk of going bust: lower than 56% of companies Debt: 2.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down 99.6%), OmniAb, Inc. would be worth roughly what it owes.
Total debt $18.9M against a stock market value of $721.1M.
Distance to default 5.79 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $9.5M (short-term plus half of long-term), stock volatility 72.3%; Altman Z'' 7.26. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down 99.6%), OmniAb, Inc. would be worth roughly what it owes.
Total debt $18.9M against a stock market value of $721.1M.
Distance to default 5.79 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $9.5M (short-term plus half of long-term), stock volatility 72.3%; Altman Z'' 7.26. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
9 relationships7
As Filer
counterparties named
2
As Counterparty
mentioned by others
3
Rel. Types
2022-03-24
Earliest Filing
2024-09-16
Latest Filing
partner: 4
investor: 2
target: 1
Counterparties (Filed by OABIW)
7 relationshipsCompanies named in OABIW's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Ligand Pharmaceuticals Incorporated | LGNZZ | partner | Former parent company of Legacy OmniAb that entered into a business combination and separation agreement. | 2022-11-07 | View |
| Avista Acquisition LP II | AVA | investor | Sponsor that purchased shares and warrants in a forward purchase agreement to backstop shareholder redemptions. | 2022-11-07 | View |
| Continental Stock Transfer & Trust Company | — | partner | Warrant agent for the Warrant Agreement. | 2022-11-07 | View |
| Computershare Trust Company, N.A. | — | partner | Counterparty to the Assignment, Assumption and Amendment Agreement regarding warrants. | 2022-11-07 | View |
| Ligand Pharmaceuticals Incorporated | LGNZZ | partner | Parent company of OmniAb entering a Reverse Morris Trust transaction to spin off its antibody discovery business. | 2022-03-24 | View |
| OmniAb, Inc. | OABIW | target | Wholly-owned subsidiary of Ligand being spun off and merged with Avista Public Acquisition Corp. II. | 2022-03-24 | View |
| Avista Acquisition LP II | AVA | investor | Sponsor of Avista Public Acquisition Corp. II entering into a forward purchase agreement and sponsor insider agreement. | 2022-03-24 | View |
Mentioned As Counterparty
2 mentionsOther companies that named OABIW in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| CNTN Tharimmune, Inc. | partner | Tharimmune has a license agreement with OmniAb to access antibody discovery technology. | 2024-09-16 | View |
| LGNZZ LIGAND PHARMACEUTICALS INC | partner | Formerly Avista Public Acquisition Corp. II (APAC), merged with Legacy OmniAb. | 2022-11-04 | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR